Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group

Sarah M. Nielsen, Diana M. Eccles, Iris L. Romero, Fahd Al-Mulla, Judith Balmaña, Michela Biancolella, Rien Blok, Maria Adelaide Caligo, Mariarosaria Calvello, Gabriele Lorenzo Capone, Pietro Cavalli, T.L. Chris Chan, Kathleen B.M. Claes, Laura...

. 2018 ; 2 () : .

Jazyk angličtina Země Spojené státy americké

Typ dokumentu práce podpořená grantem, klinická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20016281

Grantová podpora
NV15-27695A MZ0 CEP - Centrální evidence projektů
NV15-28830A MZ0 CEP - Centrální evidence projektů

Purpose: To describe a snapshot of international genetic testing practices, specifically regarding the use of multigene panels, for hereditary breast/ovarian cancers. We conducted a survey through the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium, covering questions about 16 non-BRCA1/2 genes. Methods: Data were collected via in-person and paper/electronic surveys. ENIGMA members from around the world were invited to participate. Additional information was collected via country networks in the United Kingdom and in Italy. Results: Responses from 61 cancer genetics practices across 20 countries showed that 16 genes were tested by > 50% of the centers, but only six (PALB2, TP53, PTEN, CHEK2, ATM, and BRIP1) were tested regularly. US centers tested the genes most often, whereas United Kingdom and Italian centers with no direct ENIGMA affiliation at the time of the survey were the least likely to regularly test them. Most centers tested the 16 genes through multigene panels; some centers tested TP53, PTEN, and other cancer syndrome-associated genes individually. Most centers reported (likely) pathogenic variants to patients and would test family members for such variants. Gene-specific guidelines for breast and ovarian cancer risk management were limited and differed among countries, especially with regard to starting age and type of imaging and risk-reducing surgery recommendations. Conclusion: Currently, a small number of genes beyond BRCA1/2 are routinely analyzed worldwide, and management guidelines are limited and largely based on expert opinion. To attain clinical implementation of multigene panel testing through evidence-based management practices, it is paramount that clinicians (and patients) participate in international initiatives that share panel testing data, interpret sequence variants, and collect prospective data to underpin risk estimates and evaluate the outcome of risk intervention strategies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20016281
003      
CZ-PrNML
005      
20240617111233.0
007      
ta
008      
201019s2018 xxu f 000 0|eng||
009      
AR
024    0_
$a 10.1200/PO.18.00091 $2 DOI
035    __
$a (Pubmed)31517176
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nielsen, Sarah M. $u The University of Chicago Center for Clinical Cancer Genetics, Chicago
245    10
$a Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group / $c Sarah M. Nielsen, Diana M. Eccles, Iris L. Romero, Fahd Al-Mulla, Judith Balmaña, Michela Biancolella, Rien Blok, Maria Adelaide Caligo, Mariarosaria Calvello, Gabriele Lorenzo Capone, Pietro Cavalli, T.L. Chris Chan, Kathleen B.M. Claes, Laura Cortesi, Fergus J. Couch, Miguel de la Hoya, Simona De Toffol, Orland Diez, Susan M. Domchek, Ros Eeles, Anna Efremidis, Florentia Fostira, David Goldgar, Andreas Hadjisavvas, Thomas v.O. Hansen, Akira Hirasawa, Claude Houdayer, Petra Kleiblova, Sophie Krieger, Conxi Lázaro, Maria Loizidou, Siranoush Manoukian, Arjen R. Mensenkamp, Setareh Moghadasi, Alvaro N. Monteiro, Luigi Mori, April Morrow, Nadia Naldi, Henriette R. Nielsen, Olufunmilayo I. Olopade, Nicholas S. Pachter, Edenir I. Palmero, Inge S. Pedersen, Maria Piane, Marianna Puzzo, Mark Robson, Maria Rossing, Maria Christina Sini, Angela Solano, Jana Soukupova, Gianluca Tedaldi, Manuel Teixeira, Mads Thomassen, Maria Grazia Tibiletti, Amanda Toland, Therese Törngren, Erica Vaccari, Liliana Varesco, Ana Vega, Yvonne Wallis, Barbara Wappenschmidt, Jeffrey Weitzel, Amanda B. Spurdle, Arcangela De Nicolo, and Encarna B. Gómez-García
520    9_
$a Purpose: To describe a snapshot of international genetic testing practices, specifically regarding the use of multigene panels, for hereditary breast/ovarian cancers. We conducted a survey through the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium, covering questions about 16 non-BRCA1/2 genes. Methods: Data were collected via in-person and paper/electronic surveys. ENIGMA members from around the world were invited to participate. Additional information was collected via country networks in the United Kingdom and in Italy. Results: Responses from 61 cancer genetics practices across 20 countries showed that 16 genes were tested by > 50% of the centers, but only six (PALB2, TP53, PTEN, CHEK2, ATM, and BRIP1) were tested regularly. US centers tested the genes most often, whereas United Kingdom and Italian centers with no direct ENIGMA affiliation at the time of the survey were the least likely to regularly test them. Most centers tested the 16 genes through multigene panels; some centers tested TP53, PTEN, and other cancer syndrome-associated genes individually. Most centers reported (likely) pathogenic variants to patients and would test family members for such variants. Gene-specific guidelines for breast and ovarian cancer risk management were limited and differed among countries, especially with regard to starting age and type of imaging and risk-reducing surgery recommendations. Conclusion: Currently, a small number of genes beyond BRCA1/2 are routinely analyzed worldwide, and management guidelines are limited and largely based on expert opinion. To attain clinical implementation of multigene panel testing through evidence-based management practices, it is paramount that clinicians (and patients) participate in international initiatives that share panel testing data, interpret sequence variants, and collect prospective data to underpin risk estimates and evaluate the outcome of risk intervention strategies.
650    _7
$a genetická predispozice k nemoci $x genetika $7 D020022 $2 czmesh
650    _7
$a genetické testování $x metody $7 D005820 $2 czmesh
650    17
$a nádory vaječníků $x genetika $7 D010051 $2 czmesh
650    17
$a nádory prsu $x genetika $7 D001943 $2 czmesh
650    _7
$a zárodečné mutace $x genetika $7 D018095 $2 czmesh
650    _7
$a alely $7 D000483 $2 czmesh
650    _7
$a management nemoci $7 D019468 $2 czmesh
650    _7
$a medicína založená na důkazech $7 D019317 $2 czmesh
650    _7
$a průzkumy a dotazníky $7 D011795 $2 czmesh
650    _7
$a lidé $7 D006801 $2 czmesh
650    _7
$a ženské pohlaví $7 D005260 $2 czmesh
653    00
$a ENIGMA
655    _7
$a práce podpořená grantem $7 D013485 $2 czmesh
655    _7
$a klinická studie $7 D000068397 $2 czmesh
700    1_
$a Eccles, Diana M.
700    1_
$a Romero, Iris L.
700    1_
$a Fahd Al-Mulla
700    1_
$a Al-Mulla, Fahd
700    1_
$a Balmaña, Judith
700    1_
$a Biancolella, Michela
700    1_
$a Blok, Rien
700    1_
$a Caligo, Maria Adelaide
700    1_
$a Calvello, Mariarosaria
700    1_
$a Capone, Gabriele Lorenzo
700    1_
$a Cavalli, Pietro
700    1_
$a Chan, T.L. Chris
700    1_
$a Claes, Kathleen B.M.
700    1_
$a Cortesi, Laura
700    1_
$a Couch, Fergus J.
700    1_
$a Hoya, Miguel de la
700    1_
$a De Toffol, Simona
700    1_
$a Diez, Orland
700    1_
$a Domchek, Susan M.
700    1_
$a Eeles, Ros
700    1_
$a Efremidis, Anna
700    1_
$a Fostira, Florentia
700    1_
$a Goldgar, David
700    1_
$a Hadjisavvas, Andreas
700    1_
$a Hansen, Thomas v.O.
700    1_
$a Hirasawa, Akira
700    1_
$a Houdayer, Claude
700    1_
$a Kleiblová, Petra $u Charles University, Prague, Czech Republic $7 xx0125463
700    1_
$a Krieger, Sophie
700    1_
$a Lázaro, Conxi
700    1_
$a Loizidou, Maria
700    1_
$a Manoukian, Siranoush
700    1_
$a Mensenkamp, Arjen R.
700    1_
$a Moghadasi, Setareh
700    1_
$a Monteiro, Alvaro N.
700    1_
$a Mori, Luigi
700    1_
$a Morrow, April
700    1_
$a Naldi, Nadia
700    1_
$a Nielsen, Henriette R.
700    1_
$a Olopade,Olufunmilayo I.
700    1_
$a Pachter, Nicholas S.
700    1_
$a Palmero, Edenir I.
700    1_
$a Pedersen, Inge S.
700    1_
$a Piane, Maria
700    1_
$a Puzzo, Marianna
700    1_
$a Robson, Mark
700    1_
$a Rossing, Maria
700    1_
$a Sini, Maria Christina
700    1_
$a Solano, Angela
700    1_
$a Soukupova, Jana $u Charles University, Prague, Czech Republic
700    1_
$a Tedaldi,Gianluca
700    1_
$a Teixeira, Manuel
700    1_
$a Thomassen, Mads
700    1_
$a Tibiletti, Maria Grazia
700    1_
$a Toland, Amanda
700    1_
$a Törngren, Therese
700    1_
$a Vaccari, Erica
700    1_
$a Varesco, Liliana
700    1_
$a Vega, Ana
700    1_
$a Wallis, Yvonne
700    1_
$a Wappenschmidt, Barbara
700    1_
$a Weitzel, Jeffrey
700    1_
$a Spurdle, Amanda B.
700    1_
$a Nicolo, Arcangela De
700    1_
$a Gómez-García, Encarna B.
773    0_
$t JCO precision oncology $x 2473-4284 $g Roč. 2 (2018) $w MED00204957
910    __
$a ABA008 $y 0 $z 0
990    __
$a 20201019111111 $b ABA008
991    __
$a 20240617111234 $b ABA008
999    __
$a kom $b bmc $g 1574066 $s 1106456
BAS    __
$a 3
BMC    __
$a 2018 $b 2 $x MED00204957 $i 2473-4284 $m JCO precision oncology
GRA    __
$a NV15-27695A $p MZ0
GRA    __
$a NV15-28830A $p MZ0
LZP    __
$c NLK120 $d 20240617 $a 2020-grant

Najít záznam

Citační ukazatele

Možnosti archivace